Patents Assigned to Nippon Zoki Pharmaceutical Co., Ltd.
  • Publication number: 20160089402
    Abstract: An object of the present invention is to provide an extract from inflamed skins of rabbits inoculated with vaccinia virus where the quality of the extract is more stabilized and also to provide a preparation, etc. containing said extract as an active ingredient. When the amount of sulfated tyrosine contained in an extract from inflamed skins of rabbits inoculated with vaccinia virus and also contained in a preparation containing said extract as an active ingredient is used as an index, the quality of the extract and the preparation among the manufacturing lots can be warranted as a more stabilized one. In the extract from inflamed skins of rabbits inoculated with vaccinia virus and the preparation containing said extract where the quality thereof is more stabilized by such a method, the efficacy and the safety thereof are now guaranteed more strictly resulting in very high usefulness.
    Type: Application
    Filed: April 30, 2014
    Publication date: March 31, 2016
    Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Yoshitaka NAKAZAWA, Yoji SHIBAYAMA, Ko NAKAMURA
  • Publication number: 20160010135
    Abstract: The synthesis of collagen and proteoglycan in chondrocytes, such as intervertebral disc cells, articular chondrocytes and meniscal cells is promoted by administration of an extract from inflamed tissue inoculated with vaccinia virus.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 14, 2016
    Applicants: NIPPON ZOKI PHARMACEUTICAL CO., LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Koichi MASUDA, Mitsuru NAIKI
  • Publication number: 20150322024
    Abstract: The present invention provides a cinnamic acid amide derivative having an excellent analgesic action. The cinnamic acid amide derivative of the present invention is a compound showing excellent analgesic actions to not only a nociceptive pain model animal but also a neuropathic pain model animal, which is very useful as an agent for treating various pain diseases showing acute or chronic pains or neuropathic pains.
    Type: Application
    Filed: December 27, 2013
    Publication date: November 12, 2015
    Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiro OOKUBO, Ko NAKAMURA, Yoshitaka NAKAZAWA, Hiroyoshi NANBA, Hiroyuki YOSHIDA
  • Patent number: 9150510
    Abstract: The amino acid derivative of the present invention provides a novel compound that shows excellent analgesic action. The amino acid derivative of the present invention is a novel compound that shows excellent analgesic action to not only a model animal for nociceptive pains but also a model animal for neuropathic pains, so that the amino acid derivative is very useful as a drug for treating various pain diseases.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: October 6, 2015
    Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiro Ookubo, Ko Nakamura, Hiroyoshi Nanba, Hiroyuki Yoshida, Yoshitaka Nakazawa
  • Publication number: 20150265655
    Abstract: It is an object of the present invention to provide an extract from inflamed skins of rabbits inoculated with vaccinia virus wherein the quality is more stabilized, and a preparation containing the extract, etc. The use of the amount of N-acetylneuraminic acid contained in an extract from inflamed skins of rabbits inoculated with vaccinia virus and a preparation containing the extract as an index makes possible to warrant the quality of each manufacturing lot of the extract and the preparation in more stable manner. The extract from inflamed skins of rabbits inoculated with vaccinia virus and the preparation containing the extract which are manufactured as above, and in which the quality thereof becomes more stable, are warranted to maintain efficacy and safety in more strict manner, and thus extremely useful.
    Type: Application
    Filed: October 9, 2013
    Publication date: September 24, 2015
    Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Yoshitaka Nakazawa, Yoji Shibayama, Ko Nakamura
  • Publication number: 20150232440
    Abstract: A novel coumarin derivative or a pharmaceutically acceptable salt thereof and also to provide a pharmaceutical agent containing such a compound as an active ingredient is provided. The coumarin derivative or a pharmaceutically acceptable salt thereof exhibits an excellent suppressive action to the destruction of cartilage and suppressive action to the proliferation of synovial cells in a pharmacological test where the release of sulfated glycosaminoglycans (sGAG) and the proliferation of synovial cells are used as indicators whereby it is very useful as an active ingredient of a pharmaceutical composition such as a preventive or therapeutic agent for arthropathy such as osteoarthritis or chronic rheumatoid arthritis.
    Type: Application
    Filed: September 20, 2013
    Publication date: August 20, 2015
    Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuru Naiki, Tomoyuki Okada, Kazuyoshi Sawada, Takashi Ogino
  • Patent number: 9050247
    Abstract: A pharmaceutical composition for external use which is an organogel containing a fatty acid ester and a glycerolglycerin fatty acid ester, in particular, a novel transdermally absorbabedle pharmaceutical composition for external use which has a drug such as non-narcotic analgesics as an active ingredient made in organogel form containing a drug such as non-narcotic analgesics as an active ingredient, a fatty acid ester and a glycerolglycerin fatty acid ester, and a method for producing the composition. The pharmaceutical composition significantly improves skin permeability of drugs such as non-narcotic analgesics and allows a sufficient amount of drug to permeate the skin sustainably. Moreover, since the pharmaceutical composition is in organogel form, it can be easily applied to a preparation in practice. In addition, the pharmaceutical composition can provide efficient use and the like of drugs due to a high drug release rate and therefore is highly useful.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: June 9, 2015
    Assignees: NIHON UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki Furuishi, Kazuo Tomono, Toyofumi Suzuki, Toshiro Fukami, Koji Kunimasu
  • Patent number: 9011849
    Abstract: The purpose of the present invention is to provide a medicinal agent which is useful for amelioration or treatment of chronic prostatitis, interstitial cystitis and/or urination disorders. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, it relates to an ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders containing the extract as an active ingredient. The medicinal agent of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: April 21, 2015
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventor: Makoto Tamaki
  • Patent number: 8987486
    Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: March 24, 2015
    Assignees: Nagoya Industrial Science Research Institute, Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomonori Matsumoto, Hachiro Sugimoto
  • Publication number: 20140255507
    Abstract: The synthesis of collagen and proteoglycan in chondrocytes, such as intervertebral disc cells, articular chondrocytes and meniscal cells is promoted by administration of an extract from inflamed tissue inoculated with vaccinia virus.
    Type: Application
    Filed: October 11, 2011
    Publication date: September 11, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Koichi Masuda, Mitsuru Naiki
  • Patent number: 8653285
    Abstract: An aminopropylidene derivative having excellent histamine receptor antagonistic action, a compound which is useful as a pharmaceutical composition, especially as an active ingredient, having alleviated side effects in the central nervous system is described. In the aminopropylidene derivative, R1 and R2, which may be identical or different, stand for a hydrogen, a substituted carbonyl, a substituted carbonylalkyl, and acrylic acid, excluding a case where both are hydrogen; R3 and R4, which may be identical or different, stand for hydrogen, an alkyl which may be substituted with phenyl, or the like; A stands for unsubstituted or an oxo; B stands for a carbon or an oxygen; one of X and Y stands for a carbon and the other stands for a sulfur, a broken line part stands for a single bond or a double bond, and a wavy line stands for cis-form and/or trans-form.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: February 18, 2014
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Kunihiko Higashiura, Takashi Ogino, Taizo Ito, Koji Kunimasu, Kazuhito Furukawa
  • Publication number: 20140017311
    Abstract: A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid form such as granules. The dried product may be employed to produce a solid preparation for oral administration, such as tablets, having an inhibitory activity for the production of a kallikrein-like substance.
    Type: Application
    Filed: September 19, 2013
    Publication date: January 16, 2014
    Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Masaharu KUROHASHI, Yoji SHIBAYAMA
  • Publication number: 20130345160
    Abstract: To provide a glycyrrhizin/aminoacetic acid/cysteine combination drug containing an active ingredient in high concentration and excelling in stability and safety. Stability at compounding of active ingredient in high concentration has been improved by avoiding the addition of sulfite salts having been used as a stabilizer in existing products. As glycyrrhizin high-concentration preparations, there is provided a drug composition comprising 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic acid wherein no sulfite salts are added as an additive, and pH is 6 to 7.
    Type: Application
    Filed: August 26, 2013
    Publication date: December 26, 2013
    Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Taro YOSHIKAWA, Satoshi HANAOKA
  • Patent number: 8613962
    Abstract: There is provided a medicinal agent that is effective and highly safe for the prevention or alleviation of a peripheral nerve disorder that develops as a side effect occurring after the administration of an anti-cancer agent. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and to a prophylactic or alleviating agent for a peripheral nerve disorder that contains the extract as an active ingredient. The agent containing the extract as an active ingredient is used for a prophylactic or alleviating agent for a peripheral nerve disorder induced by an anti-cancer agent and is a highly safe and remarkably highly useful medicinal agent with few side effects.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: December 24, 2013
    Assignees: Kyushu University, National University Corporation, Nippon Zoki Pharmaceutical Co., Ltd
    Inventors: Ryozo Oishi, Yoshinori Itoh, Nobuaki Egashira
  • Publication number: 20130296425
    Abstract: An object of the present invention is to provide a drug which is effective for prophylaxis or therapy of peripheral nerve disorder occurred as a side effect of the administration of anti-cancer agents. The present invention is to provide a drug containing an ester of C10 fatty acid as an active ingredient for prophylaxis or therapy of peripheral nerve disorder induced by administration of a drug containing at least one of anti-cancer agents. The drug of the present invention containing the compound as an active ingredient is highly useful as a drug for prophylaxis or therapy of peripheral nerve disorder induced by administration of anti-cancer agents.
    Type: Application
    Filed: January 30, 2012
    Publication date: November 7, 2013
    Applicants: NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomoyuki Okada, Tomonori Matsumoto, Kazuyoshi Sawada
  • Publication number: 20130296426
    Abstract: An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing an ester of C10 fatty acid as an active ingredient. The analgesic of the present invention containing the compound as an active ingredient is highly useful as a prophylactic or therapeutic agent for various pain diseases such as the pain caused by osteoarthritis (e.g., knee osteoarthritis and hip osteoarthritis) or by demyelinating diseases such as multiple sclerosis or Guillain-Bareé syndrome.
    Type: Application
    Filed: January 30, 2012
    Publication date: November 7, 2013
    Applicants: NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomoyuki Okada, Tomonori Matsumoto, Kazuyoshi Sawada
  • Patent number: 8568789
    Abstract: A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid form such as granules. The dried product may be employed to produce a solid preparation for oral administration, such as tablets, having an inhibitory activity for the production of a kallikrein-like substance.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: October 29, 2013
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Masaharu Kurohashi, Yoji Shibayama
  • Patent number: 8557864
    Abstract: A method for preventing or treating a nervous disorder can include administrating to a person in need of such prevention or treatment a pharmaceutical preparation comprising, as an active ingredient, an ester of a decenoic acid. The ester of the decenoic acid can be selected from the group consisting of trans-2-decenoic acid ethyl ester, trans-2-decenoic acid methyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid octyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-3-decenoic acid ethyl ester, trans-9-decenoic acid methyl ester, and trans-9-decenoic acid ethyl ester.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: October 15, 2013
    Assignees: Nagoya Industrial Science Research Institute, Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Munekazu Iinuma, Shoei Furukawa
  • Patent number: 8536342
    Abstract: Disclosed is a process for producing a thiabenzoazulene-propionic acid derivative which is useful as an active ingredient of an antihistaminic agent or the like. According to the producing process of the present invention, it is possible to produce a thiabenzoazulene-propionic acid derivative where the 2-position of the thiabenzoazulene skeleton is substituted with propionic acid. The thiabenzoazulene propionic-acid derivative thus synthesized has excellent antagonistic action to histamine H1 receptor and low intracerebral transmigration and, therefore, is useful as an active ingredient of the pharmaceutical composition such as an antihistaminic agent.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: September 17, 2013
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Kunihiko Higashiura, Taizo Ito, Takashi Ogino, Taisuke Hasegawa
  • Publication number: 20130225837
    Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.
    Type: Application
    Filed: November 1, 2011
    Publication date: August 29, 2013
    Applicants: Nippon Zoki Pharmaceutical Co., Ltd., Nagoya Industrial Science Research Institute
    Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomonori Matsumoto, Hachiro Sugimoto